June 30, 2021
1 min read

 Covaxin effective against both Alpha, Delta variants: US NIH

COVAXIN comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus…reports Asian Lite News

The National Institute of Health (NIH) in the United States has found that Bharat Biotech’s COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19.

The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the “highly efficacious” COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.

“Results from two studies of blood serum from people who had received COVAXIN suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively,” NIH said in a statement.

The adjuvant used in COVAXIN, Alhydroxiquim-II, was discovered and tested in the laboratory by the biotech company ViroVax LLC of Lawrence, Kansas with support exclusively from the NIAID Adjuvant Development Program, NIH said.

ALSO READ: ‘FDA decision on Covaxin has no bearing on us’

The adjuvant comprises a small molecule attached in a unique way to Alhydrogel, a substance frequently called alum that is the most commonly used adjuvant in vaccines for people.

“Ending a global pandemic requires a global response,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. “I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious COVID-19 vaccine available to people in India.”

COVAXIN comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus. Published results from a Phase 2 trial of the vaccine indicate that it is safe and well-tolerated.

Unpublished interim results from the Phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against severe COVID-19, including hospitalization, and 70 per cent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19. (ANI)

ALSO READ: Covaxin trials on children set to begin

Previous Story

Burmese grapes from Assam exported to Dubai

Next Story

Modi holds high-level meet on security issues

Latest from -Top News

World Powers Gather for G7

The leaders had unveiled its slimmed-down agenda on Sunday, prioritising discussions on the global economy and energy security….reports Asian Lite News Several world leaders have gathered at the Canadian Rockies for the

Israel Takes Out Iran Spy Leaders

Among those killed were Mohammad Khatami, head of the IRGC Intelligence Organisation since 2022, and his deputy Mohammad Hassan Mahkaghi….reports Asian Lite News Israel on Monday announced that four high-ranking Iranian intelligence

Iran May Quit Nuclear Treaty

The NPT, a landmark international treaty that came into force in 1970, seeks to prevent the spread of nuclear weapons…reports Asian Lite News Amid rising tensions with Israel, Iran announced Monday that

Modi, Cyprus President Hold Talks

Both leaders explored avenues to deepen cooperation in trade, investment, security, and technology…reports Asian Lite News Prime Minister Narendra Modi on Monday held wide-ranging discussions with Cyprus President Nikos Christodoulides at the

Jaishankar Dials UAE, Armenia as Mideast Heats Up

EAM Jaishankar discussed the fast-evolving situation and emphasised the importance of dialogue and cooperation….reports Asian Lite News External Affairs Minister S. Jaishankar held telephonic conversations with his counterparts in the United Arab
Go toTop

Don't Miss

Covaxin 77.8% effective, says Lancet

Covaxin was developed under a partnership with the Indian Council

Covaxin 77.8% effective after Phase 3 trials

Bharat Biotech’s Covaxin is overall 77.8 percent effective against Covid,